Could estrogen use be connected with a healthier aging brain?
New research involving more than 21,000 women found that those who had used estrogen-only hormone therapy later in life were less likely to develop dementia and had fewer physical signs of Alzheimer’s disease.
The research appeared August 12, 2026, in Neurology, the medical journal of the American Academy of Neurology. The authors warned that the findings cannot show that estrogen was responsible for the lower dementia risk.
Scientists have studied estrogen and the brain for years because the hormone affects much more than reproduction. Estrogen interacts with many tissues in the body, including blood vessels and brain cells, making its possible role in cognitive aging an important but complicated research question.
After menopause, the body’s production of estrogen falls sharply. Hormone therapy can replace some estrogen and is mainly prescribed to treat troublesome menopausal symptoms, rather than to prevent dementia.
Modern hormone treatment varies according to a woman’s circumstances. Women who still have a uterus generally need another hormone alongside systemic estrogen to protect the uterine lining, while estrogen-only treatment is typically reserved for women who have had a hysterectomy.
The new Stanford Medicine-led study specifically examined estrogen-only therapy. This distinction matters because previous research has suggested that estrogen alone and estrogen combined with progestin may not have the same relationship with dementia risk.
Researchers brought together information from two large groups containing 21,462 women. The women entered follow-up at an average age of about 71 and were observed for approximately three to five years.
Only 1,953 women had used hormone therapy, while 19,509 had not. An unusual feature was that hormone users had started treatment at an average age above 70, much later than the age at which hormone therapy is commonly begun today.
The researchers did not rely on just one definition of brain health. They examined dementia diagnoses and thinking abilities, but they also studied brain tissue and biological markers associated with Alzheimer’s disease.
Nearly 3,000 participants had a brain autopsy after death, at an average age of 82. An autopsy can reveal Alzheimer’s-related changes that may have been developing for years, including in people whose symptoms were not obvious during life.
Alzheimer’s disease is characterized by abnormal proteins that accumulate in the brain. Amyloid-beta forms sticky plaques between nerve cells, while tau can form abnormal tangles within cells, and both are closely studied as signs of the disease.
The researchers also considered neuritic plaques, a type of amyloid plaque surrounded by damaged nerve-cell structures. Together, these signs provided a picture of how much Alzheimer’s-related damage was present.
The differences between the groups were notable. Eighteen percent of women who had used estrogen therapy showed none of the three Alzheimer’s signs at autopsy, compared with 10% of women who had never used it.
Meanwhile, all three signs were found in 40% of hormone therapy users and 51% of nonusers. After accounting for several differences between participants, estrogen use was associated with 35% lower odds of Alzheimer’s-related changes in the brain.
Researchers adjusted for factors such as age, education, race, genetics, and high blood pressure. These adjustments are important because many characteristics besides hormone use can influence a person’s chance of developing dementia.
Another part of the research examined 728 women who had brain scans or biological-marker testing while alive. The results again suggested that women who had used estrogen had less evidence of amyloid accumulating in the brain.
Researchers measured amyloid-related markers in blood and cerebrospinal fluid, the clear liquid surrounding the brain and spinal cord. The pattern of these markers was consistent with less amyloid being trapped in brain plaques among hormone users.
The differences were not limited to laboratory measurements. Women with a history of estrogen therapy also had 39% lower odds of a clinical dementia diagnosis and were less likely to show memory loss or difficulty managing everyday activities.
Taken together, the findings create an interesting picture. Multiple measures, from daily functioning to autopsy results, suggested better brain outcomes among women who had used estrogen-only hormone therapy.
But there is a major reason not to turn this result into treatment advice. This was not a clinical trial in which similar women were randomly assigned to take estrogen or a placebo, so researchers cannot know whether estrogen itself caused the differences.
This problem is sometimes called confounding. People who receive a particular treatment can differ from people who do not in ways that affect health, even after researchers statistically adjust for many known differences.
The study also reflects hormone treatment practices from decades ago. Study author Jennifer Bruno emphasized that the timing and type of hormone use differed from today’s usual practice, so the results may not directly apply to women considering treatment now.
Current menopause care often involves considering hormone therapy closer to the start of menopause, commonly in a woman’s late 40s or 50s. Starting estrogen after age 70 is a very different situation biologically and medically.
This is especially important because previous research has raised questions about whether the brain effects of hormone therapy depend on when treatment begins. Estrogen may not have the same effects at every stage of aging, and different hormone combinations may also produce different results.
The study therefore does not establish estrogen as an Alzheimer’s prevention drug. Women should not start, stop, or change hormone therapy because of these findings without discussing their individual benefits and risks with a qualified healthcare professional.
From a research perspective, however, the study is valuable because several independent types of evidence agreed with one another. Clinical diagnoses, cognitive and daily-function measures, biomarkers, and autopsy findings all showed associations favoring the estrogen-use group.
The main weakness is that observational evidence cannot rule out all alternative explanations, and the late age of hormone use makes the study population unusual compared with current patients. The results are best viewed as a clue about how estrogen and Alzheimer’s biology may be connected, not proof of a protective treatment.
Future studies will need to examine women treated under modern hormone-therapy practices and carefully compare different starting ages, doses, treatment lengths, and hormone types. Until then, the new findings deepen scientific interest in estrogen and the brain but should not change dementia-prevention recommendations on their own.
Source: Stanford Medicine.
